Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

AstraZeneca board not swayed by £69.4bn bid

 Leif Johansson

Pfizer’s latest offer carries “significant risks”, says AstraZeneca chairman Leif Johansson

The board of UK-based AstraZeneca has until 26 May 2014 to reconsider Pfizer’s latest offer of £55 a share, putting the value of the company at £69.4bn.

Pfizer upped its offer for AstraZeneca on Sunday, but the AstraZeneca board responded by calling it “inadequate”.

The offer, according to AstraZeneca chairman Leif Johansson, would create “significant risks” for shareholders and would have “serious consequences for the company, our employees and the life-sciences sector in the UK, Sweden and the US”.

If the 26 May deadline passes with no new moves from either side it will bring to an end six months of merger talks between the two companies and Pfizer will be prevented under UK law from making a fresh approach for six months.

Pfizer refused to be drawn on whether it would make an improved bid for the company in six months time. A spokesperson said on Tuesday: “I can’t predict what will happen in the future.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138502

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.